NCT00164008

CompletedPhase 4

Comparison of Pamidronate With Zoledronic Acid for Transplan...

Bayside Health Source

Compare

Other study identifiers

Sponsor study identifier

101/02

Study Type

interventional

Actual enrollment (reported)

56

Locations

0 countries

Sites

N/A

Timeline

Study Start

October 2002

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2005

Actual (reported)

Study Completion

December 2005

Actual (reported)

Brief Summary

The purpose of this trial is to see whether zoledronic acid is better than pamidronate to treat low bone density in heart and lung transplant patients.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 56 participants
Study completion date: December 2005
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
October 2002
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 13, 2005
Actual (reported)
First Posted
September 14, 2005
Actual (reported)
Primary Completion
December 2005
Actual (reported)
Study Completion
December 2005
Actual (reported)

Last Updated: December 5, 2013
Status Verified: September 2005
Last Update Submitted: December 3, 2013

Conditions

Complications of Heart-lung Transplant Osteopenia Other Complications of Lung Transplant

Outcome Measures

Primary Outcomes (1)

Bone mineral density of lumbar spine at 12 months as measured by DEXA.

Secondary Outcomes (1)

Bone mineral density of femoral neck at 12 months as measured by DEXA.

Interventions

zoledronic acid vs pamidronateDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

reduced bone density as indicated by a bone density T score \<-1.in either the lumbar spine or femoral neck
have undergone or are on the waiting list for heart or lung transplantation

Sponsors & Collaborators

Bayside Health
Governmentlead
Novartis
Industrycollaborator

MeSH Terms

Conditions

Bone Diseases, Metabolic

Condition Hierarchy (Ancestors)

Bone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

Duncan J Topliss, MD
The Alfred
PRINCIPAL INVESTIGATOR

Enrollment

56 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER GOV
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 14, 2005

Study Start

October 2002

Date type not reported

This date has not been verified as actual or estimated.

NCT06762730

Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals

Phase 4Recruiting

NCT00168909

Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)

Phase 4Completed

NCT00211211

FREE Study - Fracture Reduction Evaluation

Phase 4Completed

NCT00504166

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

Phase 4Completed

NCT00006180

Bone Loss in Premenopausal Women With Depression

Phase 4Completed

NCT01902186

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Phase 4Terminated

are receiving adequate calcium and vitamin D therapy

have provided written informed consent prior to participation in the trial

You may not qualify if:

untreated hypogonadism, hypothyroidism or hyperthyroidism
acute or major organ rejection or intercurrent illness
pregnancy or breastfeeding

Contact the study team to confirm eligibility.

Primary Completion

December 2005

Actual (reported)

Study Completion

December 2005

Actual (reported)

Last Updated

December 5, 2013

Record last verified: 2005-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00164008
Data provider: ClinicalTrials.gov
Source updated: 2013-12-05
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:31:39 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record